Search
Femasys Inc
FEMYAdd to Watchlist
4.170USD
-0.180-4.14%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
12.59MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-4.14%
5 Days
+9.74%
1 Month
+1067.41%
6 Months
+554.94%
Year to Date
+623.71%
1 Year
+347.76%
Key Figures
4.415Open
4.780High
65.42KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.17%Turnover Ratio
4.350Prev. Close
4.170Low
185.71KTurnover
LossP/E Static
1.73P/B
0.00%Div Yield TTM
-79.84%ROA
1.34052wk High
2.36Volume Ratio
-18.82MNet Profit
3.02MShares
-0.2238EPS TTM
-2.13Beta
-255.96%ROE
0.30752wk Low
14.02%Amplitude
43.31%Gross Margin
12.59MMarket Cap
148.56Reward/Risk
7.52%Risk Rate
TradingKey Stock Score of Femasys Inc
Currency: USD Updated: 2026-07-02Key Insights
Femasys Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 110 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 63.33.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Femasys Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Femasys Inc Highlights
StrengthsRisks
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 113.93% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.29M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.29M.
Undervalued
The company’s latest PE is -18.63, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 6.18M shares, increasing 16.17% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.83.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
63.333
Target Price
+1355.94%
Upside Space
Femasys Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Femasys Inc Info
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Ticker SymbolFEMY
CompanyFemasys Inc
CEOLee-Sepsick (Kathy)
Websitehttps://www.femasys.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Femasys Inc (FEMY)?
The current price of Femasys Inc (FEMY) is 4.17.
What is the symbol of Femasys Inc?
The ticker symbol of Femasys Inc is FEMY.
What is the 52-week high of Femasys Inc?
The 52-week high of Femasys Inc is 1.34.
What is the 52-week low of Femasys Inc?
The 52-week low of Femasys Inc is 0.31.
What is the market capitalization of Femasys Inc?
The market capitalization of Femasys Inc is 248.54M.
Is Femasys Inc (FEMY) currently rated as Buy, Hold, or Sell?
According to analysts, Femasys Inc (FEMY) has an overall rating of Buy, with a price target of 63.33.